WO2007042745A1 - Chocolate based appetite suppressant - Google Patents

Chocolate based appetite suppressant Download PDF

Info

Publication number
WO2007042745A1
WO2007042745A1 PCT/GB2006/003392 GB2006003392W WO2007042745A1 WO 2007042745 A1 WO2007042745 A1 WO 2007042745A1 GB 2006003392 W GB2006003392 W GB 2006003392W WO 2007042745 A1 WO2007042745 A1 WO 2007042745A1
Authority
WO
WIPO (PCT)
Prior art keywords
theobromine
chocolate
cocoa
composition
weight
Prior art date
Application number
PCT/GB2006/003392
Other languages
French (fr)
Inventor
Albert Zumbe
Original Assignee
Albert Zumbe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Zumbe filed Critical Albert Zumbe
Publication of WO2007042745A1 publication Critical patent/WO2007042745A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/32Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/32Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
    • A23G1/48Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/32Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Definitions

  • This invention relates to compositions for appetite suppression and reducing weight in humans and/or other species that can tolerate cocoa and/or theobromine, and more particularly to compositions that contain chocolate which has been enhanced in natural theobromine or synthetic theobromine.
  • Chocolate bars normally contains in the order of 29 - 45% of fat by weight. With chocolate formulations of less than this it becomes increasingly difficult to mould and/or use the chocolate as a coating.
  • Chocolate chips usually contain between 24 - 30 % fat by weight.
  • This invention relates not to theobromine consumption alone but in the presence of chocolate, which has a synergistic effect on appetite suppression over and above the two separate components.
  • the active ingredients therefore are chocolate or chocolate extract or cocoa or cocoa extract together with enhanced concentrations of theobromine over and above the quantities normally present in standard cocoa commodities such are cocoa bean, cocoa liquor, cocoa powder and chocolate.
  • Theobromine is a known alkaloid and stimulant and it has been widely reported to have a food suppressant effect and it has been proposed in weight loss formulations, but never in formulations comprising of cocoa without the addition of over non cocoa related functional ingredients and or in formulations of chocolate without the addition of other non cocoa related functional ingredients.
  • This patent is about the synergistic effect of the individual components, namely of theobromine together with reduced fat chocolate and / or reduced fat cocoa.
  • the naturally occurring theobromine content of cocoa powder ( 10-12 % total fat ) is in the range of between 1- 2.5% by weight. In plain chocolate there is usually in the order of 0.5 - 1.5% by weight.
  • Theobromine is a mild diuretic, a mind stimulant ( on the cardiovascular system, the muscular system and the central nervous system ), it can lower the blood pressure because it can dilute the blood vessels, and also has relaxing effects creating a feeling of well being.. It has a long lasting effect in that it is broken down to about 50% in the blood stream after 6 to 10 hours. It increases the metabolic rate and stimulate the breakdown of fat ( lipolysis).
  • Overweight and obesity are chronic conditions not only associated with the social stigma of being unattractive and undesirable, but it is also associated with decreased longevity and many pathological conditions such as diabetes, varicose veins, arthritis, heart disease and cancer to name but a few.
  • Over weight and obesity is characterised by the excessive accumulation of fat in the body and as a consequence of a caloric intake that surpasses the energy expenditure. The excessive fat is not metabolised and there is a gradual deposition of fat in the body; and when this is above 20% of the ideal weight ( as described for example in the Metropolitan Height and Weight tables in Jama, 260, 2547-48, 1988 ) the person concerned is described as obese.
  • the objective of this invention is to provide a composition and regimen that is useful in helping persons not only to reduce body weight but also not to put in on in the first place.
  • Such an invention as proposed will result in maintenance of a lowered body weight over a long period with the unpleasant side effects that are commonly experienced with prescription drugs.
  • the present invention is directed to a composition comprising chocolate which is enhanced with theobromine to a level that is higher that that normally inherently present in cocoa liquor or cocoa powder.
  • Cocoa contains a number of chemical substances whose influence on human and/or animal physiology is not fully understood. These include but is not limited to for example biogenic amines such as phenylethylamine and tyramine which act as neurotransmitters. Phenylethylamine stimulates the brain in much the same way as amphetamine. Tyramine has a similar effect of epinephrine These substances effect mood swing by causing an emotional high , which can be associated with a feeling of alertness and contentment. Another class of substances are the flavenoids, and include catechin, epicatechin and proanthocyadins and are all powerful antioxidants and there role may also be implicated in the synergistic effect.
  • cocoa dies contain some caffeine. Cocoa powder usually contains about 0.1 % caffeine by weight and plain chocolate about 0.05% caffeine by weight. Caffeine is a well known stimulant although the amounts present are indeed quite small. Chocolate also contains some sugar and the rapid absorption of sugar into the blood stream will lead to a rush of glucose to the brain this may contribute to a feeling of contentment. In contract cocoa contains virtually no sugar and is considered to be a low digestible carbohydrate food.
  • cocoa reacts with the sugar in what is described as Maillard reactions which creates pleasant flavours and aromas usually associated with chocolate.
  • the conching also removes the acidic volatiles normally associated with cocoa.
  • caramelisation reactions There may also be some caramelisation reactions. It is no wonder then that chocolate has a much more pleasant taste than cocoa which is acid, bitter and somewhat astringent. For this very reason cocoa is virtually always sweetened with sugar prior to consumption.
  • compositions in this invention contain much less calories because the formulations are presented principally as dietary supplements for example capsules or tablet or gum in which over a few grams need be consumed.
  • compositions are safe and effective when used as directed and side effects are minor or none.
  • the appropriate active components may be formulated for administration by any conventional route such as rectal, nasal, topical ( dermal) or parental.
  • the composition may be in the form of tablets, capsules, suspensions, chewing gum, emulsions, solutions, suppositories, sprays or preparations that can be injected.
  • Tablets for oral use contain the active ingredients that are usually present in inert admixtures necessary for manufacturing the table for example inert diluents such as calcium carbonate, calcium phosphate, lactose sodium phosphate etc; granulating and disintegration agents such as starches, maltodextrins; and lubricating agents for example magnesium stearate or talc.
  • Other acceptable excipients include colouring agents, plasticisers, humecatants etc.
  • the tablets may optionally be coated.
  • the active ingredients of the appetite suppression compositions can also be incorporated into slow release formulations by delaying disintegration and absorption in the gastrointestinal tract.
  • Glycerol monosterate or glycerol distearate are such know substances, although many techniques are known in the art.
  • the inactive excipients in a tablet may include for example calcium carbonate, dicalcium phosphate, macrocrystalline cellulose, stearic acid, silica or magnesium stearate.
  • the active ingredients may also be incorporated into a soft or hard gel capsule either by themselves or by mixing the active ingredients with water or an oil medium such as liquid paraffin or edible oil and enclosing it within the capsule or gel capsule.
  • the active ingredients can also be administered as an oral liquid form by suspending the active ingredients in an aqueous solution in a mixture with dispersion agents, wetting agents suspension agents and preservation agents or thickening agents. These agents are when known in the art.
  • the active ingredients may also be delivered parenterally in dosage forms consistent with conventional pharmaceutically acceptable carriers and adjuvants.
  • the chocolate and cocoa components are limited soluble to extracts and synthetic theobromine or other soluble theobromine containin -g ⁇ h • erbal extracts.
  • suitable dosage forms for the active ingredients according to the present invention include suppositories ( emulsion or suspension types ), and rectal gelatins capsules ( either in solution or suspension ) .
  • suppositories emulsion or suspension types
  • rectal gelatins capsules either in solution or suspension
  • a typical suppository formulation the active principles would mixed into pharmaceutical grade cocoa butter, esterified acids, glycerinated gelatin, and acceptable water soluble or dispersible bases such as polyethylene glycols and polyethylene glycols and polyoxyehtylene sorbitan fatty acid esters.
  • formulations include for example the incorporation of theobromine ( either synthetic, or solvent extracts of chocolate or cocoa which are enriched in natural theobromine or other herbal extracts rich in theobromine ) into chocolate mass , chocolate or cocoa powder, and / or chocolate or cocoa beverage preparations incorporated in dry mixes or ready to drink beverages.
  • theobromine either synthetic, or solvent extracts of chocolate or cocoa which are enriched in natural theobromine or other herbal extracts rich in theobromine
  • This invention also includes sugar confectionery of all descriptions into which both of the appropriate active ingredients are incorporated into the formulation.
  • a feeling of appetite suppression and satiety was reported by individuals after a few days. The majority of individuals cut down on the amount they ate and did not feel the same need to snack in between meals.
  • a feeling of appetite suppression and satiety was reported by individuals after a few days. The majority of individuals cut down on the amount they ate and did not feel the same need to snack in between meals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is directed to chocolate based compositions which when consumed regularly act as an appetite suppressant, aid reduce weight and maintain weight loss over an expended period of time. The composition consists of reduced fat chocolate powder and /or chocolate extract, together with enhanced concentrations of natural theobromine or synthetic theobromine.

Description

DESCRIPTION
FIELD OF INVENTION
This invention relates to compositions for appetite suppression and reducing weight in humans and/or other species that can tolerate cocoa and/or theobromine, and more particularly to compositions that contain chocolate which has been enhanced in natural theobromine or synthetic theobromine.
BACKGROUND TO THE INVENTION
Chocolate bars normally contains in the order of 29 - 45% of fat by weight. With chocolate formulations of less than this it becomes increasingly difficult to mould and/or use the chocolate as a coating. Chocolate chips usually contain between 24 - 30 % fat by weight. This invention relates not to theobromine consumption alone but in the presence of chocolate, which has a synergistic effect on appetite suppression over and above the two separate components. The active ingredients therefore are chocolate or chocolate extract or cocoa or cocoa extract together with enhanced concentrations of theobromine over and above the quantities normally present in standard cocoa commodities such are cocoa bean, cocoa liquor, cocoa powder and chocolate.
Theobromine is a known alkaloid and stimulant and it has been widely reported to have a food suppressant effect and it has been proposed in weight loss formulations, but never in formulations comprising of cocoa without the addition of over non cocoa related functional ingredients and or in formulations of chocolate without the addition of other non cocoa related functional ingredients. This patent is about the synergistic effect of the individual components, namely of theobromine together with reduced fat chocolate and / or reduced fat cocoa.
The naturally occurring theobromine content of cocoa powder ( 10-12 % total fat ) is in the range of between 1- 2.5% by weight. In plain chocolate there is usually in the order of 0.5 - 1.5% by weight. Theobromine is a mild diuretic, a mind stimulant ( on the cardiovascular system, the muscular system and the central nervous system ), it can lower the blood pressure because it can dilute the blood vessels, and also has relaxing effects creating a feeling of well being.. It has a long lasting effect in that it is broken down to about 50% in the blood stream after 6 to 10 hours. It increases the metabolic rate and stimulate the breakdown of fat ( lipolysis).
BRIEF DESCRIPTION OF THE INVENTION.
It is a well established fact that overweight and obesity is not a healthy condition. Obesity is highly prevalent and of increasing concern to the population atiarge. It follov/s that products that aid and result in appetite suppression or resulting in weight loss would "He 'highly beneficial to a society where millions suffer from obesity, as long as the dosage is safe and effective, when taken as directed.
Overweight and obesity are chronic conditions not only associated with the social stigma of being unattractive and undesirable, but it is also associated with decreased longevity and many pathological conditions such as diabetes, varicose veins, arthritis, heart disease and cancer to name but a few. Over weight and obesity is characterised by the excessive accumulation of fat in the body and as a consequence of a caloric intake that surpasses the energy expenditure. The excessive fat is not metabolised and there is a gradual deposition of fat in the body; and when this is above 20% of the ideal weight ( as described for example in the Metropolitan Height and Weight tables in Jama, 260, 2547-48, 1988 ) the person concerned is described as obese.
The availability therefore of a dietary supplement which will suppress appetite and lead to weight loss in overweight and obese persons is highly desirable.
OBJECTIVE OF THE INVENTION
The objective of this invention is to provide a composition and regimen that is useful in helping persons not only to reduce body weight but also not to put in on in the first place. Such an invention as proposed will result in maintenance of a lowered body weight over a long period with the unpleasant side effects that are commonly experienced with prescription drugs.
DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS THEREOF
The present invention is directed to a composition comprising chocolate which is enhanced with theobromine to a level that is higher that that normally inherently present in cocoa liquor or cocoa powder. We are stating that there is synergistic effect of theobromine and other substances present in chocolate, which when consumed together on a regular basis create a stronger appetite suppression that leads to weight loss than if theobromine is consumed alone.
Cocoa contains a number of chemical substances whose influence on human and/or animal physiology is not fully understood. These include but is not limited to for example biogenic amines such as phenylethylamine and tyramine which act as neurotransmitters. Phenylethylamine stimulates the brain in much the same way as amphetamine. Tyramine has a similar effect of epinephrine These substances effect mood swing by causing an emotional high , which can be associated with a feeling of alertness and contentment. Another class of substances are the flavenoids, and include catechin, epicatechin and proanthocyadins and are all powerful antioxidants and there role may also be implicated in the synergistic effect.
It should also be mentioned that cocoa dies contain some caffeine. Cocoa powder usually contains about 0.1 % caffeine by weight and plain chocolate about 0.05% caffeine by weight. Caffeine is a well known stimulant although the amounts present are indeed quite small. Chocolate also contains some sugar and the rapid absorption of sugar into the blood stream will lead to a rush of glucose to the brain this may contribute to a feeling of contentment. In contract cocoa contains virtually no sugar and is considered to be a low digestible carbohydrate food.
More importantly, in the conching of the chocolate the cocoa reacts with the sugar in what is described as Maillard reactions which creates pleasant flavours and aromas usually associated with chocolate. The conching also removes the acidic volatiles normally associated with cocoa. There may also be some caramelisation reactions. It is no wonder then that chocolate has a much more pleasant taste than cocoa which is acid, bitter and somewhat astringent. For this very reason cocoa is virtually always sweetened with sugar prior to consumption.
We do not really understand the chemistry behind chocolate craving and many hypotheses have been presented in the scientific literature but there is something in the chocolate which may be associated to the smell and/ or taste of chocolate including cocoa, as well as the pleasure-causing anandamines in the presence of carbohydrate consumption ( i.e the sugar content of chocolate and complex carbohydrate in the cocoa), which increases the availability of the amino acid typtophan, the presursor of seratonin. Our hypothesis is that for the synergistic effect claimed in this invention the presence of one or more of these substances is important in combination of enhanced quantities of theobromine over and about the levels normally found in standard cocoa powder and chocolate.
Of course one could consume large quantities of cocoa and theobromine by eating chocolate or drinking chocolate beverages, but this would mean consuming large amounts of sugar and fat which would defeat the object as the caloric intake would increase. The compositions in this invention contain much less calories because the formulations are presented principally as dietary supplements for example capsules or tablet or gum in which over a few grams need be consumed.
These compositions are safe and effective when used as directed and side effects are minor or none.
Excellent results were obtained demonstrating appetite suppression in a clinical trial study according to the present invention in which product was administered orally either in capsules or tablets ( pills). This was a cross over study in which each participant acted as his/her own control; participants were administered the test product daily over a seven day period after which there was a seven day wash out period and seven days on a placebo. AU products were allocated blind so that the participant was unaware of whether which was the test product or placebo.
The appropriate active components may be formulated for administration by any conventional route such as rectal, nasal, topical ( dermal) or parental. The composition may be in the form of tablets, capsules, suspensions, chewing gum, emulsions, solutions, suppositories, sprays or preparations that can be injected. Tablets for oral use contain the active ingredients that are usually present in inert admixtures necessary for manufacturing the table for example inert diluents such as calcium carbonate, calcium phosphate, lactose sodium phosphate etc; granulating and disintegration agents such as starches, maltodextrins; and lubricating agents for example magnesium stearate or talc. Other acceptable excipients include colouring agents, plasticisers, humecatants etc. The tablets may optionally be coated.
The active ingredients of the appetite suppression compositions can also be incorporated into slow release formulations by delaying disintegration and absorption in the gastrointestinal tract. Glycerol monosterate or glycerol distearate are such know substances, although many techniques are known in the art.
The inactive excipients in a tablet may include for example calcium carbonate, dicalcium phosphate, macrocrystalline cellulose, stearic acid, silica or magnesium stearate. The active ingredients may also be incorporated into a soft or hard gel capsule either by themselves or by mixing the active ingredients with water or an oil medium such as liquid paraffin or edible oil and enclosing it within the capsule or gel capsule.
The active ingredients can also be administered as an oral liquid form by suspending the active ingredients in an aqueous solution in a mixture with dispersion agents, wetting agents suspension agents and preservation agents or thickening agents. These agents are when known in the art.
The active ingredients may also be delivered parenterally in dosage forms consistent with conventional pharmaceutically acceptable carriers and adjuvants. For this form of administration the chocolate and cocoa components are limited soluble to extracts and synthetic theobromine or other soluble theobromine containin -gσ h erbal extracts.
In rectal preparations, suitable dosage forms for the active ingredients according to the present invention include suppositories ( emulsion or suspension types ), and rectal gelatins capsules ( either in solution or suspension ) . A typical suppository formulation the active principles would mixed into pharmaceutical grade cocoa butter, esterified acids, glycerinated gelatin, and acceptable water soluble or dispersible bases such as polyethylene glycols and polyethylene glycols and polyoxyehtylene sorbitan fatty acid esters.
Other formulations include for example the incorporation of theobromine ( either synthetic, or solvent extracts of chocolate or cocoa which are enriched in natural theobromine or other herbal extracts rich in theobromine ) into chocolate mass , chocolate or cocoa powder, and / or chocolate or cocoa beverage preparations incorporated in dry mixes or ready to drink beverages.
This invention also includes sugar confectionery of all descriptions into which both of the appropriate active ingredients are incorporated into the formulation. This includes, candies of all description including for example hard boiled candy, toffee, jellies, gums, chewing gum, bubble gum and fondant. EXAMPLES
Example 1
Normal healthy adult individuals were given tablets containing plain chocolate powder with 65 % cocoa solids and standardised with 10% theobromine. Each tablet contained the following active ingredients, namely 30mg of theobromine and 270 mg of reduced fat chocolate. Participants were instructed to consume one tablets was about thirty minutes prior to their habitual meal times, repetitively on a daily basis. No instructions were given asking the individuals to purposely change their diet and/or modify their eating habits.
A feeling of appetite suppression and satiety was reported by individuals after a few days. The majority of individuals cut down on the amount they ate and did not feel the need to snack in between meals
Example 2
Normal healthy adult individuals were given capsules containing cocoa extract which contained 8% of theobromine and 400mg total weight ( excluding the gelatin capsule) and asked to consume two capsules before breakfast on a daily basis. No instructions were given asking individuals to purposely change their diet and/or to modify their eating habits.
A feeling of appetite suppression and satiety was reported by individuals after a few days. The majority of individuals cut down on the amount they ate and did not feel the same need to snack in between meals.
Example 3
Normal healthy adult individuals were given tablets containing cocoa powder standardised with 20% theobromine and each tablet contained 300 mg , that is 240 mg of fat free cocoa powder and 60 mg of theobromine. Individuals were asked to consume one tablet before each meal on a daily basis. No instructions were given to individuals to purposely change ihe diet and/or to modify their eating habits.
A feeling of appetite suppression and satiety was reported by individuals after a few days. The majority of individuals cut down on the amount they ate and did not feel the same need to snack in between meals.
This feeling of appetite suppression disappeared when individuals stopped consuming the tablets. ' :
Example 4.
10 grams of plain chocolate powder with 65% cocoa solids and standardised 10% theobromine was prepared and administered into sachets. Healthy adult individuals were instructed to mix the contents into 150 ml of skimmed milk or water and to consume every day at breakfast.
Individuals reported that they simply lost their appetite and reported that were struggling to eat as much as they used to.

Claims

CLAIMSWhat is claimed is:
1. Consumption of a chocolate composition comprising of enhanced levels of theobromine over and above the concentration that which would normally be found in chocolate, whereby the source of the theobromine is either from one or more of the following sources: a ) a cocoa or chocolate extract. b) synthetic theobromine c ) another non cocoa based herbal extract which contains theobromine.
2 Consumption of a chocolate composition of claim 1 whereby the chocolate is either one or a combination of the following: a) reduced fat, low fat or fat free or reduced calorie chocolate powder. b) a mixture of cocoa solids and one or more chocolate making ingredients. c) a chocolate extract d) a cocoa extract and one or more non cocoa solid chocolate making ingredient.
3. Consumption of a cocoa solids containing composition comprising of enhanced levels of theobromine over and above the concentration that which would normally be found in cocoa, whereby the source of the theobromine is either from one or more of the following sources : a ) cocoa bean extract b) cocoa liquor extract c) cocoa powder extract d) synthetic theobromine d) another non cocoa based herbal extract which contains theobromine
4. As in claims 1 & 2 whereby the composition consumed contain more than 2 % theobromine by weight.
5. As in claims 1 & 2 whereby the composition consumed contain more than 5 % theobromine by weight.
6. As in claims 1 & 2 whereby the composition consumed contain more than 10% theobromine by weight.
7. As in claims 1 & 2 whereby the composition consumed contain more than 15% theobromine by weight.
8. As in claim 3 whereby the composition consumed contain more than 3% theobromine by weight.
9. As in claim 3 whereby the composition consumed contains more than 5% theobromine by weight.
10. As in claim 3 whereby the composition consumed contains more than 12% theobromine by weight.
11. The compositions in claims 1,2 & 3 are incorporated into one or more of the following dietary supplements: a ) a capsule b) a tablet ( namely a pill ) c) a beverage ( either as a dry mix in a sachet or as a pre-prepared liquid drink) d) enteral preparations e) parenteral preparations
12. The compositions in claims 1, 2 & 3 are incorporated into one or more of the following foods : a) chocolate including sugar free and reduced fat or low fat recipes b) a cereal or meusli formulation including reduced fat or low fat recipes c) sugar confectionery d ) sugar free confectionery f) chewing gum and bubble gum g) ice cream and ice poducts
13. The compositions in claims 1,2 & 3 incorporated into dermal patches
14. The compositions in claims 1, 2 & 3 in slow release form.
15. The composition in claims 1, 2 & 3 in sustained release form.
16. The composition in claims 1, 2 or 3 whereby the effective daily dose for suppressing appetite, reducing weight and maintaining weight loss for an extended period of time contains theobromine in an amount of 30 mg or more per day.
17. Compositions as in claim 16 whereby the effective dose of theobromine is an amount of 50 mg or more per day.
18. Compositions as in claim 16 whereby the effective dose of theobromine is an amount of 100 mg or more or per day.
19. As in claim 16 whereby the effective dose of theobromine is present in an amount ranging from 150 mg to 3g per day.
20. As claim 1, 2 or 3 whereby the composition in consumed daily before breakfast.
21. As claim 1, 2 or 3 whereby the composition is consumed daily before meals.
22. Compositions as in claim 1 & 2 or whereby the chocolate contains conched chocolate and/or an extract made from conched chocolate.
23. As in claim 1, 2 & 3 whereby the total calorie intake ingested per unit dose ( i.e. per capsule or tablet or gum [ chiclet] ) is less than 5 kcal.
24. As in claim 1, 2 & 3 whwerby the total calorie intake ingested per unit dose is less than 100 kcal.
PCT/GB2006/003392 2005-10-14 2006-09-12 Chocolate based appetite suppressant WO2007042745A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0520917.6A GB0520917D0 (en) 2005-10-14 2005-10-14 Chocolate based appetite suppressant
GB0520917.6 2005-10-14

Publications (1)

Publication Number Publication Date
WO2007042745A1 true WO2007042745A1 (en) 2007-04-19

Family

ID=35451751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003392 WO2007042745A1 (en) 2005-10-14 2006-09-12 Chocolate based appetite suppressant

Country Status (2)

Country Link
GB (1) GB0520917D0 (en)
WO (1) WO2007042745A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103164A1 (en) * 2008-02-22 2009-08-27 Northern Innovations And Formulations Corp. Anti-obesity compositions comprising orlistat and various natural products
US20100173042A1 (en) * 2008-12-12 2010-07-08 Andrew McShea Chocolate extract, process of making, and uses thereof
WO2011003705A1 (en) * 2009-07-06 2011-01-13 Unilever Nv Food product containing two sections which contain a bitter tasting compound at different concentrations, and method for reducing bitterness employing said food product
EP2571502A1 (en) * 2010-05-19 2013-03-27 Unilever NV Theobromine for increasing hdl-cholesterol
US8597692B2 (en) 2007-04-26 2013-12-03 Barry Callebaut Ag Cocoa extract and use thereof
US8603547B2 (en) 2007-04-26 2013-12-10 Barry Callebaut Ag Use of cocoa extract
US8709503B2 (en) 2007-04-26 2014-04-29 Barry Callebaut Ag Use of cocoa extract
US8765191B2 (en) 2007-10-08 2014-07-01 Barry Callebaut Ag Cocoa extracts for use in providing skin benefits

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7902214A (en) * 1978-11-10 1980-05-13 Iwatani & Co METHOD FOR PREPARING COCOA POWDER
WO1998002165A1 (en) * 1996-07-17 1998-01-22 Nutracorp Scientific, Inc. Appetite suppression
EP0941666A1 (en) * 1998-03-12 1999-09-15 Societe Des Produits Nestle S.A. Reduced fat agglomerated chocolate
WO2002074321A1 (en) * 2001-03-21 2002-09-26 N.V. Nutricia Composition comprising cocoa and a dopamine d2 receptor agonist
WO2002078746A1 (en) * 2001-03-30 2002-10-10 Altaffer, Paulo Novel chocolate composition as delivery system for nutrients and medications
WO2003090673A2 (en) * 2002-04-22 2003-11-06 Rtc Research & Development, Llc. Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals
US20040180077A1 (en) * 2003-03-05 2004-09-16 Riker Donald K. Rapidly dissolving edible strips for treating obesity
WO2004082609A2 (en) * 2003-03-14 2004-09-30 Pro-Health, Inc. Composition and method for appetite and carving suppression and mood enhancement
WO2006034463A2 (en) * 2004-09-23 2006-03-30 Herbalife International, Inc. Herbal supplement to support weight loss

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7902214A (en) * 1978-11-10 1980-05-13 Iwatani & Co METHOD FOR PREPARING COCOA POWDER
WO1998002165A1 (en) * 1996-07-17 1998-01-22 Nutracorp Scientific, Inc. Appetite suppression
EP0941666A1 (en) * 1998-03-12 1999-09-15 Societe Des Produits Nestle S.A. Reduced fat agglomerated chocolate
WO2002074321A1 (en) * 2001-03-21 2002-09-26 N.V. Nutricia Composition comprising cocoa and a dopamine d2 receptor agonist
WO2002078746A1 (en) * 2001-03-30 2002-10-10 Altaffer, Paulo Novel chocolate composition as delivery system for nutrients and medications
US20020192316A1 (en) * 2001-03-30 2002-12-19 Paulo Altaffer Novel chocolate composition as delivery system for nutrients and medications
WO2003090673A2 (en) * 2002-04-22 2003-11-06 Rtc Research & Development, Llc. Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals
US20040180077A1 (en) * 2003-03-05 2004-09-16 Riker Donald K. Rapidly dissolving edible strips for treating obesity
WO2004082609A2 (en) * 2003-03-14 2004-09-30 Pro-Health, Inc. Composition and method for appetite and carving suppression and mood enhancement
WO2006034463A2 (en) * 2004-09-23 2006-03-30 Herbalife International, Inc. Herbal supplement to support weight loss

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597692B2 (en) 2007-04-26 2013-12-03 Barry Callebaut Ag Cocoa extract and use thereof
US8603547B2 (en) 2007-04-26 2013-12-10 Barry Callebaut Ag Use of cocoa extract
US8709503B2 (en) 2007-04-26 2014-04-29 Barry Callebaut Ag Use of cocoa extract
US8765191B2 (en) 2007-10-08 2014-07-01 Barry Callebaut Ag Cocoa extracts for use in providing skin benefits
WO2009103164A1 (en) * 2008-02-22 2009-08-27 Northern Innovations And Formulations Corp. Anti-obesity compositions comprising orlistat and various natural products
US20100173042A1 (en) * 2008-12-12 2010-07-08 Andrew McShea Chocolate extract, process of making, and uses thereof
WO2011003705A1 (en) * 2009-07-06 2011-01-13 Unilever Nv Food product containing two sections which contain a bitter tasting compound at different concentrations, and method for reducing bitterness employing said food product
EP2571502A1 (en) * 2010-05-19 2013-03-27 Unilever NV Theobromine for increasing hdl-cholesterol
EP2571502B1 (en) * 2010-05-19 2016-04-27 Unilever N.V. Theobromine for increasing hdl-cholesterol
US11806352B2 (en) 2010-05-19 2023-11-07 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol

Also Published As

Publication number Publication date
GB0520917D0 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
US9387168B2 (en) Chewing gum with tomatidine
EP1383537B1 (en) Novel chocolate composition as delivery system for nutrients and medications
US7115285B2 (en) Composition and method for appetite and craving suppression and mood enhancement
US20060127452A1 (en) Method and composition for reducing cravings for a craved substance
US20180104299A1 (en) Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity
KR101214391B1 (en) Glycine-containing food and use thereof
WO2007042745A1 (en) Chocolate based appetite suppressant
KR20080030633A (en) Method of treatment or management of stress
Kelishadi Cacao to cocoa to chocolate: healthy food?
US20060094734A1 (en) Composition and method for inducing alertness
JP2006503099A (en) Composition for reducing caloric intake
JP7090849B2 (en) Liver function improving composition and liver function improving food composition
WO2004045605A1 (en) Use of flavonoid for the treatment of overweight and the reduction of the mammalian appetite
US7371415B1 (en) Method and composition for improving sexual fitness
US9253991B2 (en) Chewing gum with B vitamins
JPH0995448A (en) Increase in biotin concentration in blood and biotin-containing beverage or food product
JPH1025245A (en) Oral hypnotic agent, hypnotic beverage and food, and hypnotic feed
CA2410966C (en) Sexual desire and performance enhancement with protein-bound tryptophan
US20050214362A1 (en) Appetite suppressant
KR100729847B1 (en) Zinc gluconate mixture which was good taste and masked to bitter taste of Zinc gluconate
KR100596318B1 (en) Healthy foods containing butterbur extract for memory ability improvement
US20020187179A1 (en) Non-steroidal anabolic compositions and associated methods
US20140335222A1 (en) Spray Method and Composition for Reducing Psychological Hunger
JP2001299242A (en) Food containing gelling agent and method for producing the same
KR20240146137A (en) Sensory activator composition, sensory activator including the same and method of fabricating thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06779406

Country of ref document: EP

Kind code of ref document: A1